2020
- What outcomes data are available for cefiderocol in the treatment of serious, resistant infections?
- What evidence supports the use of oliceridine for severe pain?
- Is there information on intrawound/topical vancomycin powder in craniotomy?
- Is oral vancomycin prophylaxis (OVP) beneficial for secondary prevention of Clostridioides difficile infection (CDI)?
- What are the pharmacologic options for managing pica in pregnant women?
- Update: What evidence is available on the off-label use of dexmedetomidine for alcohol withdrawal syndrome?
- Update: What evidence supports the use of direct-acting oral anticoagulants in patients with cancer-related VTE?
- How should unfractionated heparin be monitored in patients transitioning from oral factor Xa inhibitors?
- What is the role of dapagliflozin for treatment of heart failure?
- What data supports imipenem-cilastatin/relebactam’s new indication for bacterial pneumonia?
- What information is available regarding screening and treating asymptomatic bacteriuria prior to select nonurologic surgeries?
- Update: What data support the use of andexanet alfa (ANDEXXA) for the reversal of factor Xa inhibitors?
- What do pharmacists need to know about the Emergency Use Authorization for convalescent plasma for COVID-19?
- What efficacy supports the use of liposomal bupivacaine for post-Cesarean pain control?
- Are there data to support the use of IV meloxicam for perioperative pain control in orthopedic surgery patients?
- What evidence supports transitioning from dexmedetomidine to clonidine for sedation management?
- What recommendations are available for laboratory monitoring of direct oral anticoagulants (DOAC)?
- What drugs should be avoided in myasthenia gravis?
- What is the controversy surrounding testosterone replacement therapy?
- What information is available regarding use of anticoagulation in the management of COVID-19?
- What information is available regarding the risks of ACE inhibitor or ARB use during the COVID-19 pandemic?
- What data are there to support use of tocilizumab in critically ill patients with COVID-19?
- What evidence supports the use of colchicine for secondary prevention after an acute myocardial infarction?
- What information is available regarding the use of chloroquine or hydroxychloroquine for treatment of COVID-19?
- Are there data to support the use of oral albuterol for acute respiratory symptoms when inhalation treatment is unavailable or inappropriate?
- What evidence supports the use of tranexamic acid in patients with traumatic brain injury?
- What is the evidence available for treatment of COVID-19 with lopinavir/ritonavir or remdesivir?
- What should I, as a pharmacist, know about COVID-19?
- What literature is available for the use of inhaled tranexamic acid in hemoptysis?
- Is there literature describing the efficacy or safety of inhaled vancomycin to treat MRSA ventilator-associated tracheobronchitis?
- What is the new recommendation for 13-valent pneumococcal vaccine in elderly adults?
- Is melatonin an effective treatment option for the prevention of hospital-induced delirium?
- What evidence supports the use of oral tranexamic acid for major orthopedic surgery?
- What evidence is available comparing pegfilgrastim administration on day of versus day after chemotherapy?
- What data are available to support the use of bisphosphonates in calciphylaxis?
- What information is available on use of water-soluble contrast agents for uncomplicated adhesive small bowel obstruction?
- What is the recommended frequency and duration of electrocardiogram monitoring in patients receiving intravenous haloperidol?